> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Cumberland Recruiting MS Study Participants
- URL: https://www.fdaweb.com/cumberland-recruiting-ms-study-participants/
- Published: 2021-08-26T12:00:00.000Z
- Updated: 2026-09-14T17:12:07.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150019

Cumberland Pharmaceuticals says it is looking for 48 Duchenne muscular dystrophy (DMD) patients age 7 and older for a Phase 2 FIGHT DMD study funded by FDA to evaluate the safety, efficacy, and duration of effect of its oral ifetroban therapy for cardiomyopathy linked to DMD. A company [statement](https://musculardystrophynews.com/2021/08/26/1st-fda-funded-dmd-study-ifetroban-recruiting-patients-heart-disease/?ref=fdaweb.com) says the study will be conducted at various U.S. locations and will assess participants’ heart and lung function, muscle strength, daily activity, and quality of life.

Ifetroban is described as an inhibitor of the thromboxane receptor that works by reducing fibrosis and fat deposits in the heart. Cumberland says a study has shown that it prevents scarring of the heart tissue and improved survival in mouse models of muscular dystrophy.

FDA awarded Cumberland $1 million from the orphan product grant program to support the trial.